Topic immunotherapy with 5% imiquimod in complex clinical scenarios of basal cell skin cancer
Lytvynenko B.V. 1,2, Litus M.O.2
Summary. The aim of the study was to evaluate the efficacy and tolerability of topical immunotherapy with 5% imiquimod in patients with basal cell carcinoma (BCC), including H-zone tumors and multiple lesions in Gorlin syndrome, taking into account the European Association of Dermato-Oncology (EADO) classification (2021). Three clinical cases are presented with morphological verification of the diagnosis, EADO staging and multidisciplinary definition of treatment tactics; imiquimod was used according to standard regimens with dynamic clinical and dermatoscopic control. In all cases, clinical remission with good cosmetic results was achieved; local inflammatory reactions correlated with therapeutic response and were controlled. Therefore, imiquimod can be considered as an effective non-invasive alternative to surgery in carefully selected patients, subject to regular monitoring.
Leave a comment